Scandinavian ChemoTech AB Series B (ST:CMOTEC-B) — Stock Price
Scandinavian ChemoTech AB Series B (ST:CMOTEC-B) is currently trading at Skr3.40 SEK, up 5.92% today. Over the past 52 weeks, shares have ranged between Skr3.01 and Skr7.30. This page tracks Scandinavian ChemoTech AB Series B's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Scandinavian ChemoTech AB Series B worth.
Scandinavian ChemoTech AB Series B (CMOTEC-B) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Scandinavian ChemoTech AB Series B's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Scandinavian ChemoTech AB Series B Income Statement — Revenue, Profit & Earnings by Year
Scandinavian ChemoTech AB Series B's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Skr12.29 Million | Skr6.57 Million | Skr2.82 Million | Skr473.00K | Skr49.00K |
| Cost of Revenue | Skr18.59 Million | Skr1.79 Million | Skr1.17 Million | Skr528.00K | Skr-274.00K |
| Gross Profit | Skr-6.30 Million | Skr4.78 Million | Skr1.66 Million | Skr-55.00K | Skr323.00K |
| Research & Development | — | Skr1.90 Million | Skr2.57 Million | Skr2.91 Million | Skr2.77 Million |
| SG&A | Skr3.15 Million | Skr5.31 Million | Skr5.82 Million | Skr6.08 Million | Skr4.74 Million |
| Total Operating Expenses | Skr18.75 Million | Skr17.57 Million | Skr21.89 Million | Skr20.86 Million | Skr19.94 Million |
| Operating Income | Skr-6.30 Million | Skr-12.80 Million | Skr-20.24 Million | Skr-20.91 Million | Skr-17.08 Million |
| EBITDA | Skr-4.33 Million | Skr-12.38 Million | Skr-19.58 Million | Skr-20.81 Million | Skr-17.03 Million |
| EBIT | Skr-6.30 Million | Skr-12.54 Million | Skr-19.69 Million | Skr-20.85 Million | Skr-17.07 Million |
| Interest Expense | Skr1.59 Million | Skr1.18 Million | Skr1.40 Million | Skr1.90 Million | Skr675.00K |
| Income Before Tax | Skr-8.06 Million | Skr-13.72 Million | Skr-21.09 Million | Skr-22.75 Million | Skr-17.74 Million |
| Income Tax Expense | — | — | Skr2.51 Million | Skr1.83 Million | Skr675.00K |
| Net Income | Skr-8.06 Million | Skr-13.72 Million | Skr-21.09 Million | Skr-22.75 Million | Skr-17.74 Million |
Scandinavian ChemoTech AB Series B Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Scandinavian ChemoTech AB Series B's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Skr13.20 Million | Skr13.38 Million | Skr14.87 Million | Skr21.70 Million | Skr25.81 Million |
| Total Current Assets | Skr9.14 Million | Skr7.77 Million | Skr7.20 Million | Skr11.82 Million | Skr13.44 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr2.68 Million | Skr3.51 Million | Skr2.24 Million | Skr2.87 Million | Skr2.50 Million |
| Inventory | Skr2.79 Million | Skr3.31 Million | Skr4.03 Million | Skr3.10 Million | Skr2.25 Million |
| Property, Plant & Equipment | Skr119.00K | Skr4.00K | Skr12.00K | Skr35.00K | Skr73.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr10.01 Million | Skr7.40 Million | Skr3.84 Million | Skr7.71 Million | Skr1.89 Million |
| Total Current Liabilities | Skr10.01 Million | Skr7.40 Million | Skr3.84 Million | Skr7.71 Million | Skr1.89 Million |
| Long-term Debt | — | — | — | Skr0.00 | Skr53.00K |
| Net Debt | Skr-3.67 Million | Skr-949.00K | Skr-923.00K | Skr-5.85 Million | Skr-8.63 Million |
| Total Stockholder Equity | Skr3.19 Million | Skr5.98 Million | Skr11.03 Million | Skr13.99 Million | Skr23.92 Million |
| Retained Earnings | Skr-8.06 Million | Skr-13.72 Million | Skr-21.09 Million | Skr-22.75 Million | Skr-17.74 Million |
Scandinavian ChemoTech AB Series B Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Scandinavian ChemoTech AB Series B generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-3.75 Million | Skr-13.14 Million | Skr-18.23 Million | Skr-19.63 Million | Skr-19.18 Million |
| Capital Expenditures | Skr437.00K | Skr46.00K | Skr680.00K | Skr331.00K | Skr3.18 Million |
| Free Cash Flow | Skr-4.18 Million | Skr-13.19 Million | Skr-18.91 Million | Skr-19.96 Million | Skr-22.36 Million |
| Investing Cash Flow | Skr-426.00K | Skr-2.00K | Skr-468.00K | Skr-603.00K | Skr-3.33 Million |
| Financing Cash Flow | Skr6.89 Million | Skr13.17 Million | Skr13.77 Million | Skr17.26 Million | Skr29.71 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr1.97 Million | Skr2.06 Million | Skr2.68 Million | Skr2.95 Million | Skr2.82 Million |
| Change in Cash | Skr2.72 Million | Skr26.00K | Skr-4.93 Million | Skr-2.83 Million | Skr7.20 Million |
Scandinavian ChemoTech AB Series B Earnings History — EPS Actual vs. Analyst Estimates
Track Scandinavian ChemoTech AB Series B's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 29, 2026 | -0.06 | — | — |
| Mar 04, 2026 | -0.10 | — | — |
| Nov 05, 2025 | -0.05 | — | — |
| Aug 13, 2025 | -0.04 | — | — |
| May 06, 2025 | -0.14 | — | — |
| Mar 04, 2025 | -0.14 | — | — |
| Nov 05, 2024 | -0.14 | — | — |
| Aug 13, 2024 | -0.18 | — | — |